1. Diagnostic criteria: IDH wild-type GBM is one of the core indicators for diagnosing IDH wild-type GBM according to the WHO.2. Prognostic assessment: Patients need to be comprehensively judged by combining their ligand expression levels and TP53 status to identify subgroups of patients with extremely poor prognoses.3. Treatment target: TERT is an important candidate molecule for targeted therapy, although targeted therapies against EGFR are available. This evidence concerns the gene EGFR and glioblastoma.